350 rub
Journal №12 for 2011 г.
Article in number:
The Apoptosis Induction in vitro Cultured MCF-7 Breast Cancer Cells by the Novel Somatostatin Analog Cifetrelin
Keywords: breast cancer MCF-7 somatostatin apoptosis р53 NF-kB
Authors:
M.A. Krasil-nikov, E.I. Mikhaevich
Abstract:
To date the somatostatin analogues are the object of interest as potential antitumor agents. A number of somatostatin-like compounds were synthesized. They are used in the therapy of neuroendocrinal tumors, the potential of their use in the therapy of other tumors is being actively investigated. Here, we studied the mechanism of antitumor action of a novel somatostatin analogue cifetrelin on in vitro cultured breast cancer cells MCF-7. We found that cifetrelin has an increased cytostatic activity compared to somatostatin. In the lower concentrations, that do not cause growth inhibition, cifetrelin significantly promotes the apoptosis, induced by adriamycin. We have revealed, that cytostatic activity of cifetrelin is the result of apoptosis induction, apoptosis is p53-independent and is accompanied by the early NF-kB inhibition. In general, the data obtained demonstrate a high level of antitumor activity of cifetrelin in breast cancer cells. The further studies are required to elicit the mechanism of cifetrelin action and its possible use in therapy of malignant diseases.
Pages: 45-50
References
  1. De Herder W.W., Lamberts S.W. Somatostatin and somatostatin analogues: diagnostic and therapeutic uses // Curr Opin Oncol. 2002. V. 14(1). Р. 53-7.
  2. Dolan J.T., Miltenburg D.M., Granchi T.S., Miller C.C. 3rd, Brunicardi F.C. Treatment of metastatic breast cancer with somatostatin analogues a meta-analysis // Ann Surg Oncol. 2001. V. 8(3). P. 227-33.
  3. Gasparian A.V., Yao Y.J., Kowalczyk D. et al. The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells // J. Cell. Sci. 2002. V. 115. P. 141-151.
  4. Hotz M.A., Gong J., Traganos F. et al. // Cytometry. 1994. V. 15. № 3. P. 237 - 244.
  5. Krasil'nikov M.A., Shatskaya V.A., Stavrovskaya A.A. et al. // Biochim Biophys Acta. 1999. V. 1450. № 3. P. 434-443.
  6. Pollak M. The potential role of somatostatin analogues in breast cancer treatment // Yale J Biol Med. 1997. V. 70(5-6). Р. 535-9.
  7. Setyono-Han B., Henkelman M.S., Foekens J.A., Klijn J.G.M. Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells // Cancer Res. 1987. V. 47. Р. 1566-1570.
  8. Slawson C., Copeland R.J., Hart G.W. O-GlcNAc signaling: a metabolic link between diabetes and cancer - // Trends Biochem Sci. 2010. V. 35(10). P. 547-55.
  9. Susini C., Buscail L. Rationale for the use of somatostatin analogs as antitumour agents // Annals of Oncology. 2006. V. 17/12. P. 1733-1742.
  10. Weckbecker G., Lewis I., Albert R., Schmid H.A. et. al. Opportunities in somatostatin research: biological, chemical and therapeutic aspects // Nature Rev. Drug Discovery. 2003. V. 2. P. 999-1017.
  11. Егоров А.В., Кондрашин С.А., Фоминых Е.В., Мусаев Г.Х., Гитель Е.П., Гуревич Л.Е., Парнова Л.А., Васильев И.А., Рабинович Э.З., Волков Р.Ю. Аналоги соматостатина в диагностике и лечении нейроэндокринных опухолей // Анналы хирургической гепатологии. 2009. Т. 14. № 4. С. 1-7.
  12. Красильников М.А., Лузай Е.В., Щербаков А.М. и др. // Биохимия. 2004. Т. 69. № 3. С. 399-409.
  13. Патент № 2254139 (РФ). Средство, обладающее противоопухолевым действием / Л.И. Смирнова, С.В. Устинкина, А.П. Смирнова, О.Л. Орлова, Н.А. Оборотова, З.С. Смирнова, И.Ю. Кубасова, З.С. Шпрах.